Optimal duration of adjuvant trastuzumab therapy in patients with HER2-possitive early breast cancer: whether the problem is resolved?

Por L G Zhukova, I P Ganshina, E I Khatkova, T E Tikhomirova, O E Kondratyeva
Publicado em 2018-06-01

Olaparib in the metastatic HER2-negative breast cancer setting

Por L. G. Zhukova, E. I. Khatkova, I. P. Ganshina, I. V. Kolyadina, E. V. Lubennikova
Publicado em 2020-12-01

Role of palbociclib in the treatment of hormone receptor-positive HER2-negative metastatic breast cancer. Generalizing results of randomized trials and real clinical practice

Por L. G. Zhukova, E. I. Khatkova, P. S. Feoklistova, K. S. Grechukhina, S. A. Smolin, E. A. Arutyunyan, E. M. Kolyago
Publicado em 2019-06-01

The use of regorafenib in patients with disseminated gastrointestinal stromal tumours. A review of the literature. A clinical case

Por D. A. Filonenko, S. V. Petukhova, E. I. Khatkova, K. A. Vorontsova, E. I. Chichikov, B. M. Medvedeva, L. G. Zhukova
Publicado em 2018-07-01

Target therapy of luminal HER2-negative advanced breast cancer with PIK3CA mutation: combination of alpelisib plus fulvestrant in real clinical practice

Por D. A. Filonenko, T. M. Ibragimova, N. I. Polshina, A. V. Belogurova, E. I. Khatkova, E. A. Arutiunian, E. I. Volkova, L. G. Zhukova
Publicado em 2021-12-01